Cardiovascular disease (CVD) remains the leading driver of global mortality, claiming an estimated 17.9 million lives every year. While we often focus on prevention in middle age, the clinical reality is that age is the most significant non-modifiable risk factor. In fact, 70% of individuals over the age of 70 will develop some form of CVD.
For clinicians, managing this population isn’t just about following standard guidelines—it’s about navigating a unique set of physiological and pharmacological challenges.
The complexity of the aging heart
Treating CVD in older adults requires a high index of suspicion because the “classic” clinical picture often disappears:
- Atypical presentation: Older patients are less likely to report crushing chest pain. Instead, myocardial ischemia may present as sudden confusion, falls, extreme fatigue, or persistent nausea.
- Altered physiology: Aging naturally leads to arterial stiffening and reduced renal clearance. This means that standard drug doses can quickly become toxic, increasing the risk of adverse drug reactions (ADRs).
- Comorbidities: Managing heart disease alongside conditions like chronic kidney disease or dementia is a delicate balancing act. The more medications a patient takes, the higher the likelihood of interactions that can worsen cardiac outcomes.
Want to learn more?
Assessing risk in the elderly requires a specialized toolkit to ensure you are protecting the heart without compromising overall safety.
Check out this free course to help you master these strategies. CVD Risk in Older Adults: Strategies for Safer Medication Use provides evidence-based insights into risk stratification and in older adults.